Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops before surgery may tame inflammation in retinal detachment

NCT ID NCT07162818

Disease control Sponsor: Indonesia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether nepafenac 0.1% eye drops, given before surgery, can lower inflammation in people with retinal detachment. Sixty-one adults used the drops or a placebo for five days before surgery. Researchers measured inflammatory markers in the eye fluid. The goal is to see if this simple treatment could help prevent a complication called proliferative vitreoretinopathy (PVR), which can cause surgical failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nepafenac 0.1% eye drops
What this could lead to
If it works, this could point toward a simple eye drop treatment before surgery to reduce inflammation and prevent scarring in retinal detachment.
What could go wrong
This is a small, early-phase study measuring biomarkers, not clinical outcomes. The drops may not actually prevent vision loss or scarring in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

61 people

The number who actually took part.

Started

Apr 2021

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ARR with PVR grade A and B * ARR onset more than 7 days and less than 1 month * Macula off * ARR patients with a minimum age of 18 years. * Willing to follow the research stages and sign the informed consent. Exclusion Criteria: * ARR patients with media opacities that do not allow fundus examination * History of undergoing intraocular surgery less than 3 months. * ARR patients with comorbid eye diseases. * ARR patients with systemic complications that make it impossible to undergo vitrectomy surgery. * ARR sufferers who are known to have a history of allergies to the NSAID group.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Proliferative vitreoretinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

proliferative vitreoretinopathy rhegmatogenous retinal detachment

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Proliferative vitreoretinopathy Rhegmatogenous retinal detachment

Contacts and locations

Locations

  • Department of Ophthalmology, Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo Hospital

    Jakarta, Jakarta Pusat, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.